Context Therapeutics is trading at $0.59 (5.1% down) in after-hours trading as broader market weakness and thin liquidity weigh on the small-cap biotech.
- There are no fresh company-specific filings, trial updates, or analyst actions linked to the downward move.
- The decline appears tied to general risk-off sentiment, with broader indices falling more than 1.8%.
- The stock has slipped below Wednesday’s regular-session close following a volatile week for the biotech sector.